Supernus Pharmaceuticals, Inc.
SUPN
$48.27
$1.122.38%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 219.06M | 207.71M | 211.57M | 192.10M | 165.45M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 219.06M | 207.71M | 211.57M | 192.10M | 165.45M |
| Cost of Revenue | 63.13M | 62.83M | 50.83M | 48.33M | 38.94M |
| Gross Profit | 155.93M | 144.88M | 160.74M | 143.77M | 126.51M |
| SG&A Expenses | 136.04M | 126.67M | 124.44M | 110.97M | 94.55M |
| Depreciation & Amortization | 25.33M | 25.64M | 24.53M | 24.33M | 20.82M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 224.50M | 215.15M | 199.80M | 183.63M | 154.31M |
| Operating Income | -5.44M | -7.44M | 11.77M | 8.48M | 11.14M |
| Income Before Tax | -57.65M | -5.95M | -1.91M | -57.95M | 16.67M |
| Income Tax Expenses | 723.00K | -3.66M | 2.19M | -12.84M | -5.83M |
| Earnings from Continuing Operations | -58.37M | -2.29M | -4.11M | -45.12M | 22.50M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -58.37M | -2.29M | -4.11M | -45.12M | 22.50M |
| EBIT | -5.44M | -7.44M | 11.77M | 8.48M | 11.14M |
| EBITDA | 20.30M | 18.69M | 36.79M | 33.28M | 32.50M |
| EPS Basic | -1.01 | -0.04 | -0.07 | -0.80 | 0.40 |
| Normalized Basic EPS | -0.06 | -0.05 | 0.16 | 0.12 | 0.17 |
| EPS Diluted | -1.01 | -0.04 | -0.07 | -0.80 | 0.40 |
| Normalized Diluted EPS | -0.06 | -0.05 | 0.16 | 0.12 | 0.17 |
| Average Basic Shares Outstanding | 58.07M | 57.65M | 57.34M | 56.55M | 56.02M |
| Average Diluted Shares Outstanding | 58.07M | 57.65M | 57.34M | 56.55M | 56.64M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |